活药物工程化对抗:CAR - t细胞治疗的综合综述。

Saasha Vinoo, Divya Jaiswal, Palak Mehta, Atharv Battu, Anuradha Majumdar
{"title":"活药物工程化对抗:CAR - t细胞治疗的综合综述。","authors":"Saasha Vinoo, Divya Jaiswal, Palak Mehta, Atharv Battu, Anuradha Majumdar","doi":"10.18502/ijhoscr.v19i2.18555","DOIUrl":null,"url":null,"abstract":"<p><p>The plethora of advancements in cancer treatment has resulted in designing unique signatures and personalized therapies, tailored to patient-specific needs, using medications that target specific markers on cancer cells or even retrain the body's immune system. Chimeric Antigen Receptor T-cell, also called as CAR T-cell, is one such approach wherein a patient's cells are modulated to kill the cancer cells. Conventional cancer treatments invite issues like low specificity, increased chances of relapse, or issues with radiotoxicity and tolerance in the case of chemotherapy. Currently, CAR T-cell therapy is under clinical investigation, and different countries are still coming up with their guidelines for the pragmatic application of CAR T. In this review, we present all one needs to know about CAR T-cell therapy, its types, components, side effects, current authorization status in different countries, along with the technology being used in the therapy. We also briefly upon the recent regulations or guidelines released by Europe and the USA, the countries that have actively initiated the CAR T idea. This review aims to provide insight into this targeted therapy, which has the potential to boost cancer research and to help researchers develop more such patient-specific treatments to improve clinical outcomes in cancer.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 2","pages":"180-190"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368713/pdf/","citationCount":"0","resultStr":"{\"title\":\"Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.\",\"authors\":\"Saasha Vinoo, Divya Jaiswal, Palak Mehta, Atharv Battu, Anuradha Majumdar\",\"doi\":\"10.18502/ijhoscr.v19i2.18555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The plethora of advancements in cancer treatment has resulted in designing unique signatures and personalized therapies, tailored to patient-specific needs, using medications that target specific markers on cancer cells or even retrain the body's immune system. Chimeric Antigen Receptor T-cell, also called as CAR T-cell, is one such approach wherein a patient's cells are modulated to kill the cancer cells. Conventional cancer treatments invite issues like low specificity, increased chances of relapse, or issues with radiotoxicity and tolerance in the case of chemotherapy. Currently, CAR T-cell therapy is under clinical investigation, and different countries are still coming up with their guidelines for the pragmatic application of CAR T. In this review, we present all one needs to know about CAR T-cell therapy, its types, components, side effects, current authorization status in different countries, along with the technology being used in the therapy. We also briefly upon the recent regulations or guidelines released by Europe and the USA, the countries that have actively initiated the CAR T idea. This review aims to provide insight into this targeted therapy, which has the potential to boost cancer research and to help researchers develop more such patient-specific treatments to improve clinical outcomes in cancer.</p>\",\"PeriodicalId\":94048,\"journal\":{\"name\":\"International journal of hematology-oncology and stem cell research\",\"volume\":\"19 2\",\"pages\":\"180-190\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368713/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of hematology-oncology and stem cell research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/ijhoscr.v19i2.18555\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hematology-oncology and stem cell research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijhoscr.v19i2.18555","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

癌症治疗方面的大量进步导致设计出独特的特征和个性化的治疗方法,根据患者的特定需求量身定制,使用针对癌细胞上特定标记的药物,甚至重新训练人体的免疫系统。嵌合抗原受体t细胞,也被称为CAR - t细胞,就是这样一种方法,通过调节患者的细胞来杀死癌细胞。传统的癌症治疗方法存在一些问题,如低特异性,复发的机会增加,或者在化疗的情况下存在放射毒性和耐受性问题。目前,CAR - t细胞疗法正处于临床研究阶段,不同国家仍在制定CAR - t的实际应用指南。在这篇综述中,我们介绍了所有人们需要知道的关于CAR - t细胞疗法,它的类型,成分,副作用,目前在不同国家的授权状况,以及在治疗中使用的技术。我们还简要介绍了欧洲和美国最近发布的法规或指导方针,这些国家积极发起了CAR - T的想法。这篇综述旨在深入了解这种靶向治疗,它有可能促进癌症研究,并帮助研究人员开发出更多针对患者的治疗方法,以改善癌症的临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.

Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.

Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.

The plethora of advancements in cancer treatment has resulted in designing unique signatures and personalized therapies, tailored to patient-specific needs, using medications that target specific markers on cancer cells or even retrain the body's immune system. Chimeric Antigen Receptor T-cell, also called as CAR T-cell, is one such approach wherein a patient's cells are modulated to kill the cancer cells. Conventional cancer treatments invite issues like low specificity, increased chances of relapse, or issues with radiotoxicity and tolerance in the case of chemotherapy. Currently, CAR T-cell therapy is under clinical investigation, and different countries are still coming up with their guidelines for the pragmatic application of CAR T. In this review, we present all one needs to know about CAR T-cell therapy, its types, components, side effects, current authorization status in different countries, along with the technology being used in the therapy. We also briefly upon the recent regulations or guidelines released by Europe and the USA, the countries that have actively initiated the CAR T idea. This review aims to provide insight into this targeted therapy, which has the potential to boost cancer research and to help researchers develop more such patient-specific treatments to improve clinical outcomes in cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信